Why India’s massive cancer drugs price drop may not benefit all
There is now a cap on the high margins earned by distributors, but where pharma firms themselves charge exorbitant rates, the intervention offers little relief
Attributed summary
There is now a cap on the high margins earned by distributors, but where pharma firms themselves charge exorbitant rates, the intervention offers little relief
Read the original report — India Today
Storywire publishes attributed summaries for discoverability. Full reporting remains with the original publisher — we do not republish restricted full text.
